A systematic approach for identifying shared mechanisms in epilepsy and its comorbidities
暂无分享,去创建一个
Martin Hofmann-Apitius | Charles Tapley Hoyt | Daniel Domingo-Fernández | Nora Balzer | Anka Güldenpfennig | M. Hofmann-Apitius | Nora R. Balzer | D. Domingo-Fernándéz | Anka Güldenpfennig | Nora Balzer
[1] Florence Pasquier,et al. Phenotype associated with APP duplication in five families. , 2006, Brain : a journal of neurology.
[2] Steven Petrou,et al. The Mechanism of Carbamazepine Aggravation of Absence Seizures , 2006, Journal of Pharmacology and Experimental Therapeutics.
[3] K. Staley. Molecular mechanisms of epilepsy , 2015, Nature Neuroscience.
[4] Woong Sun,et al. Early growth response 1 (Egr‐1) directly regulates GABAA receptor α2, α4, and θ subunits in the hippocampus , 2015, Journal of neurochemistry.
[5] Martin Hofmann-Apitius,et al. Mining biomarker information in biomedical literature , 2012, BMC Medical Informatics and Decision Making.
[6] Charles Tapley Hoyt,et al. PyBEL: a computational framework for Biological Expression Language , 2017, Bioinform..
[7] H. Steiner,et al. Genes and mechanisms involved in β-amyloid generation and Alzheimer’s disease , 1999, European Archives of Psychiatry and Clinical Neuroscience.
[8] R. Connors,et al. Evidence for a shared genetic susceptibility to migraine and epilepsy , 2013, Epilepsia.
[9] P. Tariot,et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. , 1998, The American journal of psychiatry.
[10] Ted Slater,et al. Recent advances in modeling languages for pathway maps and computable biological networks. , 2014, Drug discovery today.
[11] R Bellazzi,et al. Big Data and Biomedical Informatics: A Challenging Opportunity , 2014, Yearbook of Medical Informatics.
[12] J R Storey,et al. Topiramate in Migraine Prevention: A Double‐Blind, Placebo‐Controlled Study , 2001, Headache.
[13] Filippo S. Giorgi,et al. The role of norepinephrine in epilepsy: from the bench to the bedside , 2004, Neuroscience & Biobehavioral Reviews.
[14] Moran Gal,et al. Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells. , 2003, Gene.
[15] Yaakov Stern,et al. Incidence and Predictors of Seizures in Patients with Alzheimer's Disease , 2006, Epilepsia.
[16] M. Doran,et al. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin–1 gene , 2006, Journal of Neurology.
[17] R. S. Jones,et al. The action of anticonvulsant drugs on the firing of locus coeruleus neurons: selective, activating effect of carbamazepine. , 1983, European journal of pharmacology.
[18] Run Wang,et al. Evaluating the Effectiveness of GTM-1, Rapamycin, and Carbamazepine on Autophagy and Alzheimer Disease , 2017, Medical science monitor : international medical journal of experimental and clinical research.
[19] Sang Hong Lee,et al. Estimation of pleiotropy between complex diseases using single-nucleotide polymorphism-derived genomic relationships and restricted maximum likelihood , 2012, Bioinform..
[20] Josemir W Sander,et al. Effects of topiramate on cognitive function , 2000, Journal of neurology, neurosurgery, and psychiatry.
[21] Josemir W Sander,et al. Comorbidities of epilepsy: current concepts and future perspectives , 2016, The Lancet Neurology.
[22] L. Mucke,et al. Epilepsy and cognitive impairments in Alzheimer disease. , 2009, Archives of neurology.
[23] S. Masino,et al. Adenosine receptors and epilepsy: current evidence and future potential. , 2014, International review of neurobiology.
[24] Francisco Sales,et al. Ontology and Knowledge Management System on Epilepsy and Epileptic Seizures , 2010, SWAT4LS.
[25] M. Solas,et al. Treatment Options in Alzheimer´s Disease: The GABA Story. , 2015, Current pharmaceutical design.
[26] Mohammad Asif Emon,et al. Multimodal mechanistic signatures for neurodegenerative diseases (NeuroMMSig): a web server for mechanism enrichment , 2017, Bioinform..
[27] Martin Hofmann-Apitius,et al. Computable cause-and-effect models of healthy and Alzheimer's disease states and their mechanistic differential analysis , 2015, Alzheimer's & Dementia.
[28] Dietmar R. Thal,et al. Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.
[29] A. Algra,et al. Cognitive impairment in tuberous sclerosis complex is a multifactorial condition , 2008, Neurology.
[30] B. Scatton,et al. Modulation of the gamma-aminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. , 1995, Molecular pharmacology.
[31] Samuel Wiebe,et al. Somatic Comorbidity of Epilepsy in the General Population in Canada , 2005, Epilepsia.
[32] John F Rothrock. Topiramate for Migraine Prevention: An Update , 2012, Headache.
[33] Patrício Soares-da-Silva,et al. Mechanisms of Action of Carbamazepine and Its Derivatives, Oxcarbazepine, BIA 2-093, and BIA 2-024 , 2002, Neurochemical Research.
[34] Qiang Lu,et al. A polymorphism in CALHM1 is associated with temporal lobe epilepsy , 2011, Epilepsy & Behavior.
[35] W. Le,et al. Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-β pathology in a mouse model of Alzheimer's disease. , 2013, Current Alzheimer research.
[36] Martin Hofmann-Apitius,et al. Towards a Pathway Inventory of the Human Brain for Modeling Disease Mechanisms Underlying Neurodegeneration. , 2016, Journal of Alzheimer's disease : JAD.
[37] Jeffrey Noebels,et al. A perfect storm: Converging paths of epilepsy and Alzheimer’s dementia intersect in the hippocampal formation , 2011, Epilepsia.
[38] Clementina Boniver,et al. Comorbidity between headache and epilepsy in a pediatric headache center , 2010, The Journal of Headache and Pain.
[39] M. Murphy,et al. Alzheimer's disease and the amyloid-beta peptide. , 2010, Journal of Alzheimer's disease : JAD.
[40] Richard W Newton,et al. The underlying etiology of infantile spasms (West syndrome): Information from the United Kingdom Infantile Spasms Study (UKISS) on contemporary causes and their classification 2 , 2010, Epilepsia.
[41] Sonia Maria Dozzi Brucki,et al. Epilepsy in patients with Alzheimer's disease: A systematic review , 2014, Dementia & neuropsychologia.
[42] James B Leverenz,et al. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. , 2010, Brain : a journal of neurology.
[43] Detlev Boison,et al. Adenosine and Seizure Termination: Endogenous Mechanisms , 2013, Epilepsy currents.
[44] R. Altman,et al. Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.
[45] J. H. Cross,et al. ILAE Official Report: A practical clinical definition of epilepsy , 2014, Epilepsia.
[46] Guojun Bu,et al. Implications of GABAergic Neurotransmission in Alzheimer’s Disease , 2016, Front. Aging Neurosci..
[47] Josemir W Sander. Comorbidity and premature mortality in epilepsy , 2013, The Lancet.
[48] Dulaney A Wilson,et al. Epilepsy beyond seizure: A population-based study of comorbidities , 2014, Epilepsy Research.
[49] Tim Pearson,et al. Adrenoceptor subtype‐specific acceleration of the hypoxic depression of excitatory synaptic transmission in area CA1 of the rat hippocampus , 2004, The European journal of neuroscience.
[50] D. Treiman. GABAergic Mechanisms in Epilepsy , 2001, Epilepsia.
[51] Bruce Hermann,et al. Association of epilepsy and comorbid conditions. , 2009, Future neurology.
[52] Peter Mariën,et al. Cerebellar cognitive affective syndrome associated with topiramate , 2008, Clinical Neurology and Neurosurgery.